| Item type |
☆紀要論文 / Departmental Bulletin Paper(1) |
| 公開日 |
2014-08-17 |
| タイトル |
|
|
タイトル |
<Cases Reports> Achievement of complete molecular response by the switch from imatinib to dasatinib in a patient with chronic myeloid leukemia in chronic phase |
|
言語 |
en |
| 著者 |
Murakami, Haruo
Wada, Yusuke
Ueda, Koji
Nagare, Yasuaki
Urase, Fumiaki
|
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
chronic myeloid leukemia, 2ndgeneration TKI, imatinib, dasatinib |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 著者 所属 |
|
|
値 |
Department of Hematology Sakai Hospital, Kinki University Faculty of Medicine |
| 著者 所属 |
|
|
値 |
Department of Hematology Sakai Hospital, Kinki University Faculty of Medicine |
| 著者 所属 |
|
|
値 |
Department of Hematology Sakai Hospital, Kinki University Faculty of Medicine |
| 著者 所属 |
|
|
値 |
Department of Hematology Sakai Hospital, Kinki University Faculty of Medicine |
| 著者 所属 |
|
|
値 |
Department of Hematology Sakai Hospital, Kinki University Faculty of Medicine |
| 著者所属(翻訳) |
|
|
値 |
Kinki University |
| 著者所属(翻訳) |
|
|
値 |
Kinki University |
| 著者所属(翻訳) |
|
|
値 |
Kinki University |
| 著者所属(翻訳) |
|
|
値 |
Kinki University |
| 著者所属(翻訳) |
|
|
値 |
Kinki University |
| 版 |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 出版者 名前 |
|
|
出版者 |
Kinki University Medical Association |
| 書誌情報 |
en : ACTA MEDICA KINKI UNIVERSITY
巻 39,
号 1,
p. 57-63,
発行日 2014-06-01
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
03866092 |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
[Abstract] The prognosis of chronic myeloid leukemia (CML) in chronic phase (CP) have been greatly improved by a tyrosine kinase inhibitor (TKI),imatinib. However, some patients show resistance or intolerance to imatinib. For such patients, more potent 2^nd generation TKIs, nilotinib and dasatinib, were developed, and have been shown to be effective for imatinib resistant/intolerant cases. We here report a case with CML-CP, who had been treated with interferon (IFN) and hydroxycarbamide (HU) since 1999. Although complete hematologic response was achieved by IFN+HU, any cytogenetic response was not obtained. So, we changed IFN + HU to imatinib from 2002. She achieved complete cytogenetic response and major molecular response at 18 and 44 months from the start of imatinib, respectively. However, minimum residual disease (MRD) was still detected by thenested PCR at 94 months. In addition, she complained of side effects of imatinib, general fatigue and muscle clumps. So, we changed imatinib to dasatinib. Without any side effect of dasatinib, MRD became undetectable twelve months after the switch to dasatinib. This case suggests that the switch from imatinib to 2^nd TKI would be a useful option for CML-CP patients with MRD and/or side effects in terms of both efficacy and quality of life. |
| フォーマット |
|
|
内容記述タイプ |
Other |
|
内容記述 |
application/pdf |
AA0050842X-20140600-0057.pdf (6.3 MB)
